BioSpace News Archive

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with an anti PD-1 and chemotherapy.

InMode Ltd., a leading global provider of innovative medical technologies, announced financial results for the third quarter ended September 30, 2019.

Smart Decision, Inc. (OTC Pink Markets: SDEC), a next-generation consumer-based LED & CBD algorithm innovator, is pleased to announce that it has signed a Letter of Intent (LOI) with LBC Bioscience Inc., a visionary in the CBD space.

The Canadian Aboriginal AIDS Network (CAAN) announces Indigenous leadership and supporters will celebrate Aboriginal AIDS Awareness Week December 1 – 6, 2019. It will launch in Ottawa, ON with a Parliamentary Tea followed by events across the country

Contract from National Institutes of Health (NIH) is Largest of Four Prime Contracts Awarded IRISYS Since 2010

The U.S. Food and Drug Administration (FDA) has awarded AnaBios an exclusive Indefinite Delivery Indefinite Quantity (IDIQ) contract to employ adult human primary tissues and cardiomyocytes from organ donors to assess drug safety related to cardiac function.

Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.

Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, announced the upcoming presentation of preclinical data from its Immune-Stimulating Antibody Conjugate platform at the 34th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland.

Compugen Ltd. disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti-PVRIG antibody, in patients with advanced solid tumors. COM701 was well-tolerated with no dose-limiting toxicities observed.

IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.